Our results suggest that MHY1487, a radiosensitizer and an mTOR activator39, and Reolysin, an oncolytic virus derived from dsRNA45 that is currently being studied in phase II and III trials for NSCLC and head and neck squamous cell carcinoma (NCT01708993 and NCT01166542), might be effective additions to combination therapy comprising immunotherapy and RT. Here, MTOR is linked to head and neck squamous cell carcinoma.